PEB.NZX
Pacific Edge Limited
Our view
You need to become a client or login to see Forsyth Barr’s current view.
Recent research View all research
About Pacific Edge Limited
Pacific Edge is a cancer diagnostics company in the early stages of commercialisation of its first product, Cxbladder, after 10 years of research into genetic markers. Cxbladder is a suite of non-invasive urine tests to detect the presence of bladder cancer in patients presenting with haematuria. PEB has two products in the market, Cxbladder Detect and Cxbladder Triage, with an eventual target of four to six Cxbladder products. PEB also has a suite of products in various stages of development for melanoma, colorectal cancer, endometrial cancer and gastric cancer.
Forsyth Barr Analyst
-
Chelsea Leadbetter, Senior Analyst, Equities
[email protected]
DDI: +64 4 495 5262